Associated Papers
The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.
Avolio M et al.
Cancer Discovery, 2026
40981426 (PubMed )
Supplement: cd-24-0556_supplementary_table_s2_suppst2.xlsx › Top_genes_effects_
Loss of HES1 Expression is Associated with Extracellular Matrix Remodeling and Tumor Immune Suppression in KRAS Mutant Colon Adenocarcinomas.
Wang L et al.
Research Square, 2023
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer.
Durinikova E et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2022
35881546 (PubMed )
Supplement: EMS151756-supplement-Table_S1.xlsx › Cell_lines
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY et al.
Genome Medicine, 2021
34059130 (PubMed )
Supplement: 13073_2021_898_MOESM3_ESM.xlsx › SuppTable1
Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups.
Egan C et al.
Haematologica, 2020
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Mendes-Pereira AM et al.
Embo Molecular Medicine, 2009
20049735 (PubMed )
Supplement: emmm0001-0315-SD1.pdf
Select a paper to view details